Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd commenced trading on 3 Feb 2026 with a significant gap up, opening 5.98% higher than its previous close. This robust start outpaced the Pharmaceuticals & Biotechnology sector’s gain of 2.66%, signalling a notably positive market response amid a day that saw the stock reach an intraday high of Rs 182.6, an 8.05% increase.

Jagsonpal Pharmaceuticals Ltd has seen a marked shift in its valuation parameters, moving from an expensive to a very expensive rating, raising concerns about its price attractiveness relative to historical levels and peer benchmarks. Despite a recent uptick in share price, the company’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest investors should carefully weigh the risks amid a challenging sector backdrop.

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Jagsonpal Pharmaceuticals Ltd has touched a new 52-week low of Rs.158.5 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology industry.

Jagsonpal Pharmaceuticals Ltd has touched a new 52-week low of Rs.165 today, marking a significant decline amid broader market pressures and company-specific valuation concerns. The stock has underperformed its sector and benchmark indices, reflecting a challenging period for the pharmaceutical firm.

Jagsonpal Pharmaceuticals Ltd’s stock declined to a fresh 52-week low of Rs.168.7 on 20 Jan 2026, marking a significant downturn amid a broader market pullback. The stock has underperformed its sector and benchmark indices, reflecting ongoing valuation concerns despite recent profit growth.

Jagsonpal Pharmaceuticals Ltd has touched a new 52-week low of Rs.174.5 today, marking a significant decline in its stock price amid broader market fluctuations and company-specific valuation concerns.

Jagsonpal Pharmaceuticals Ltd’s stock declined to a fresh 52-week low of Rs.178 on 12 Jan 2026, marking a significant downturn amid broader market weakness and sector underperformance. The stock’s recent trajectory reflects a combination of valuation concerns and relative underperformance against benchmarks.

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Jagsonpal Pharmaceuticals Ltd has touched a new 52-week low of Rs.181.35 today, marking a significant decline in its stock price amid broader market fluctuations and sectoral pressures. The stock’s recent performance reflects a continuation of downward momentum, with notable underperformance relative to its sector and benchmark indices.

Jagsonpal Pharmaceuticals Ltd has declined to a fresh 52-week low of Rs.186, marking a significant downturn in its stock performance amid broader market fluctuations and company-specific valuation concerns.

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Jagsonpal Pharmaceuticals Ltd has touched a new 52-week low of Rs.189.9 today, marking a significant decline amid a broader market environment where the Sensex remains resilient. The stock has underperformed its sector and broader indices, reflecting a challenging period for the company within the Pharmaceuticals & Biotechnology industry.

Jagsonpal Pharmaceuticals Ltd has reached a new 52-week low of Rs.191.2, marking a significant decline in its stock price amid broader market fluctuations and company-specific valuation concerns.

Jagsonpal Pharmaceuticals Ltd has touched a new 52-week low, closing at Rs 192.5, marking a significant decline in its stock price amid a sustained downward trend over recent sessions.

Jagsonpal Pharmaceuticals has reached a new 52-week low of Rs.192.5, reflecting a continuation of recent downward momentum amid broader market fluctuations and sector-specific dynamics.

Jagsonpal Pharma has experienced a revision in its evaluation metrics, reflecting a shift in market assessment driven by a combination of valuation concerns, technical indicators, and financial trends. This adjustment comes amid a challenging performance backdrop for the pharmaceutical small-cap, which has seen notable fluctuations in returns over recent periods.

Jagsonpal Pharmaceuticals has experienced a notable shift in its technical momentum, with recent evaluation adjustments signalling a bearish trend across multiple timeframes. The stock’s price movement and technical indicators suggest a cautious outlook amid broader market dynamics.